Clinical Trial Update: Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients [NA]

View source ↗

Summary

A completed clinical trial evaluating whether adding raltegravir to antiretroviral therapy reduces persistent CNS immune activation in treated HIV-1 patients, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: University of California, San Francisco | Conditions: HIV Infections | NA | Status: COMPLETED | Results posted: 2013-07-05